
Doctors Without Borders USA's CEO On Leadership And Smooth Transitions
So why is Avril Benoît, CEO of Doctors Without Borders/Médecins Sans Frontières (MSF) USA, stepping down now? In May she announced she was leaving the post, and the organization will announce her successor in the coming months. Benoît, a 2023 Forbes 50 Over 50: Impact honoree, told me the timing is built in at MSF, which limits its CEOs to six-year terms.
'You're totally throwing yourself into a job that becomes a lifestyle,' she said. 'It's all-consuming in many respects. You're having to consume and experience vicariously, often from a distance, all the harrowing circumstances of a humanitarian crisis. And all of that weighs on you so heavily while you're trying to drive forward and lead. I think the thinking is that by having people potentially return to operations, or give the operational people an opportunity to lead from headquarters, is just a healthy dynamic, especially for an action-oriented organization like us. We really are very passionate. We're impatient, we're hard driving, we're on the ground. And there's only so long, I would argue, that you can really sustain that.'
Benoît's term as CEO of MSF USA concludes almost two decades with the humanitarian nonprofit organization, and she said she's not necessarily leaving it completely behind. The former broadcast journalist has seen a lot in terms of events and management experience.
Today's Forbes CEO newsletter is all about Benoît's leadership at MSF USA, looking at its similarities to other U.S. businesses, as well as key differences; how she's handled major challenges; and what she and the organization are doing to ensure a smooth leadership transition. This is the published version of Forbes' CEO newsletter, which offers the latest news for today's and tomorrow's business leaders and decision makers. Click here to get it delivered to your inbox every week. A SECOND CAREER
Doctors Without Borders USA CEO Avril Benoît. Doctors Without Borders/Médecins Sans Frontières
Benoît said she's been helping people for her entire professional life, but the first 20 years were from a different perspective. Her first career was as a radio, TV and print journalist, working for the Canadian Broadcasting Corporation for two decades. Benoît said she entered journalism with a real desire to contribute to the public good.
On the air, she presented stories that showcased inequality and need around the world. Off hours, she volunteered for a variety of causes and helped them raise money. While still a journalist, she chaired the board of a group of women dedicated to raising money for girls and women worldwide to receive an education.
'I was spending so much time doing that: volunteering,' she said. 'Always just loving the experience of being a volunteer, and wondering can I ever imagine leveraging my background to help an organization and really become one of the doers—as opposed to somebody, as a journalist, who is just chronicling, who's telling the stories, who's trying to amplify—but really get in there. Is there something I can offer?'
Her opportunity came in 2006 when MSF Canada was looking for a director of communications. She landed the job, and became more inspired as time went by and wanted to know more. She learned about the places and situations in which MSF worked, but her education went deeper. She learned about how the organization conducts its operations—how it assesses situations, how teams and logistics are organized, how they negotiate access in the midst of difficult situations.
As the now-59-year-old's children got older and left the house, she had more time to spend with MSF. She worked not only on the operational side of the organization, but also in the field. As she climbed the ladder at MSF, leading projects in South Africa, South Sudan and Mauritania, and moving into organizational communication and fundraising roles, she always believed MSF's field work MSF was its most important duty. As a senior leader of the organization, including as USA CEO, Benoît says she's worked in the field in Ukraine, Sudan, Chad and the Democratic Republic of Congo.
'Almost the equivalent of walking the shop floor for a CEO, but not just walking the shop floor. Actually doing the work,' she said. DIFFERENCES AND SIMILARITIES
Avril Benoît speaks to a patient in Katsina, in northwest Nigeria, where a 2024 MSF study found extremely critical levels of malnutrition. © Sarah Nuhu/MSF
MSF is an international organization that brings medical and humanitarian assistance to people affected by conflict, epidemics, disasters and healthcare exclusion. It's a big company with a huge mission. Benoît's work as U.S. CEO is to provide leadership and support for that mission—from doing advocacy work in Washington, D.C., and around the nation to fundraising. More than 30% of MSF's total global funds come from the U.S., Benoît said, and they do not rely on the federal government for financial support.
Her typical day could include figuring out operational and logistical support for operations—much like the leader of any company, though with potentially bigger consequences, considering many of their operations are in dangerous places. But it could also include ordinary HR decisions.
Because MSF is an international organization, Benoît is also a part of strategic discussions: Where will they invest their funds and how will they take positions on simmering conflicts. These can be tense debates, she said, because the stakes are high and it's difficult to forecast the best course of action to do the most good. And they aren't necessarily limited to executives.
'We foster a culture of debate because we know that whether you're the CEO or you're the water and sanitation technician on the ground, you have a valid perspective to offer,' Benoît said. 'And so to be a leader in the organization means that you have to take space for it, and it's much less hierarchical than perhaps many other organizations.'
Benoît said that sometimes people in the for-profit business world dismiss those leading organizations like MSF because they are paid less, assuming that nonprofit executives and employees must be less competent. That's definitely not the case, she said.
'There's so much to commend this kind of work: that's meaningful and where you not only get the motivation of whatever intrinsic value it gives to you as an individual in terms of dealing with complex challenges of forever being stimulated, of always in a learning organization, but also the extrinsic ones where you're helping others in a very concrete way,' Benoît said. 'There's a lot of value in this kind of organization, and it's one of the reasons that we attract such good people.' RAISING AWARENESS
A building belonging to Doctors Without Borders (MSF) in the southern Gaza Strip last year. Majdi Fathi/NurPhoto via Getty Images
The last six years have seen wars, humanitarian crises and a global pandemic, creating new challenges for MSF. Benoît said she's tried as a leader to not impose her ideas on how to meet these challenges. The people on the ground who are closer to the situation and can more clearly see what the best solutions would be.
Fundraising has been one of her strong points. From 2019 to 2024, MSF USA raised more than $3.75 billion—an overall increase of nearly 81.5%.
'You can always do higher-quality medicine,' Benoît said. 'There are always more needs. There are always gaps in terms of humanitarian assistance available to people in crisis at a time when they need us most. We want to be able to step up. …I never got into all this work thinking I would be so often making the case for support to the public, to small groups and individuals on Zoom calls or in-person. And yet I feel so passionately about the efforts of the organization, and that we do need this help.'
She's also worked to spread the word about what MSF is doing. Many people want to help the world and just need to be asked. And, Benoît said, MSF is a vital proxy organization because they help people in need throughout the world, both in places that people know—like Gaza—and ones that they haven't heard so much about. SMOOTH TRANSITIONS
A Doctors Without Borders ship offloaded migrants rescued in the Mediterranean Sea in Italy in 2024. Roberto Serra -For an organization like MSF, there is never an 'easy time' for change. But Benoît said she has confidence in the organization. She doesn't personally play a role in selecting her successor; that's the job of the board. However, she said, there are what she describes as high-quality people throughout the organization.
The person who should take on the job, Benoît said, should be ready to take on a wide range of challenges. But they should also be able to debate the best solutions, keep themselves on a livable pace in a world that always wants bigger, better, faster, more, and manage expectations for what can be done. And, Benoît said, come into the experience rested, resilient and adaptable.
'One of the things that we're trying to navigate in this moment of volatility and polarization in the U.S. is how to keep being true to who we are, what we do in the world, evolving as necessary for the sake of the patients and the communities, and maintaining that courage of our convictions, of being there for people when they need us most,' Benoît said. 'And there's a lot of effort that we're doing for the sake of my successor, just to make sure when I hand them the torch, the handle is not on fire.' COMINGS + GOINGS Fast food franchise Subway announced that Jonathan Fitzpatrick will join the company as chief executive officer, effective July 28. Fitzpatrick previously worked as president and CEO of Driven Brands, and will be replacing John Chidsey, who left in December 2024.
announced that will join the company as chief executive officer, effective July 28. Fitzpatrick previously worked as president and CEO of Driven Brands, and will be replacing John Chidsey, who left in December 2024. Dental equipment manufacturer Dentsply Sirona appointed Daniel Scavilla as chief executive officer, effective August 1. Scavilla most recently worked as president and CEO of Globus Medical, and succeeds Simon Campion.
appointed as chief executive officer, effective August 1. Scavilla most recently worked as president and CEO of Globus Medical, and succeeds Simon Campion. Beverage bottling firm Refresco selected Steve Presley to be its next chief executive officer, effective August 4. Presley joins the company from Nestlé where he worked as executive vice president and chief executive officer of Zone Americas, and will succeed Hans Roelofs.
Send us C-suite transition news at forbescsuite@forbes.com STRATEGIES + ADVICE
In these times, most business leaders would say they are dealing with a variety of crises. But instead of viewing them as complex problems to solve, it's better to reframe your mindset and look at them as opportunities.
To make better decisions, look at your data insights closely. They can tell you what's been going on with your company, as well as what would best result in growth. QUIZ
An interaction last week between President Donald Trump and Federal Reserve Chair Jerome Powell caught on video went viral. What happened?
A. Powell corrected Trump and clarified that Trump actually nominated him to chair the Fed, not former President Joe Biden
B. Powell told Trump his estimates for construction at Fed headquarters were wrong and included previously completed work
C. Powell looked at Trump incredulously as he talked about the economic benefits of the One Big Beautiful Bill Act and tariffs
D. Trump called Powell a 'numbskull' to his face, and Powell responded, 'Excuse me?'
See if you got the answer right here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Machinify to acquire Performant Healthcare for $670m
New Mountain Capital's portfolio company Machinify has signed a definitive agreement to acquire Performant Healthcare, a company in payment integrity, for around $670m. With the merger agreement, shareholders of Performant are set to receive $7.75 in cash for each outstanding share, a 139% premium over the 90-day volume-weighted average price of $3.25 as of 31 July 2025. New Mountain Capital Private Equity managing director and president Matt Holt said: 'The future of the US healthcare system requires modernisation of IT infrastructure, including patient-centric data networks. 'Performant plus Machinify plus the ecosystem of companies that we are building at New Mountain Capital will unlock the potential for a new system that is aligned with a more productive care model that is both more efficient and delivers better patient outcomes.' The acquisition is anticipated to be finalised by the end of this year, subject to closing conditions, encompassing approval from the shareholders of Performant and regulatory clearances. Machinify CEO David Pierre said: 'At Machinify, we are creating the modern, healthcare payments intelligence platform built for accuracy and transparency. 'By combining our powerful payer operating system with Performant's trusted domain expertise and differentiated data assets, Machinify will support a broader range of clients, including the Centers for Medicare and Medicaid, and state and local governments. The combined company will deliver quality, timely payments at dramatically reduced administrative costs.' Performant is required to maintain its business operations as usual until the transaction is completed. The company's board of directors has given unanimous approval for the deal. Pillsbury Winthrop Shaw Pittman is serving as legal counsel, while Truist Securities is providing exclusive financial advisory services to Performant. JP Morgan Securities is advising Machinify exclusively on financial aspects, with Ropes & Gray providing legal counsel. "Machinify to acquire Performant Healthcare for $670m" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Donald Trump's Latest Boast Breaks Math Brains Across The Internet
Donald Trump's math on cutting drug prices didn't add up. Again. The president this weekend repeated his worthwhile promise to get pharma companies to lower the cost of medications for Americans, who often have to pay much more for certain drugs than people abroad. But the actual amount of the 'tremendous drop' in cost that Trump boasted about had critics scratching their heads. 'You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500%,' said Trump, 'I don't mean 50%. I mean 14, 1,500%,' he added. But as many on social media pointed out, that would mean all drugs are free and people actually get paid to receive them. Also, drug prices haven't actually reduced yet, despite Trump's pressure on pharmaceutical companies. Trump appeared to acknowledge that when he later said, 'We'll be dropping drug prices by 1,200, 1,300 and even 1,400% and 500% but not just 50% or 25% which normally would be a lot because the rest of the world pays much less for the identical drug.' Reality is 'eroding before our eyes,' said one critic. Others agreed. Related... Ex-Prosecutor Says Probe Into Jack Smith Is Actually 'Last Thing' Trump Should Want Kamala Harris Stuns Colbert With Candid Admission: 'To Hear You Say That… Is Harrowing' Watch MAGA Brains Break When Jordan Klepper Talks About Trump And Epstein Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Blood Platelet Market Outlook Report 2025-2030: Increased Use of Donated Blood Platelets in Regenerative Medicine and Biotechnology
The global blood platelet market is set to expand from $3.2 billion in 2025 to $4 billion by 2030, growing at a CAGR of 4.6%. Key players include the American National Red Cross and Canadian Blood Services. The market spans hospitals, cancer treatment centers, and more, covering North America, Europe, Asia-Pacific, and beyond. Blood Platelet Market Dublin, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The "Blood Platelet Market" report has been added to global market for blood platelets is expected to grow from $3.2 billion in 2025 and is projected to reach $4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 4.6% during the forecast period of 2025 to 2030. Some key organizations in the blood platelet market are the American National Red Cross, Vitalant, Canadian Blood Services, NHS Blood and Transplant and the Red Cross Society of China. These leading organizations run extensive platelet collection, testing and distribution networks. They ensure timely access to safe, high-quality blood products in the nations where they are located. Their commitment to product innovation, donor outreach and regulatory compliance is crucial to improving the efficiency and reliability of the blood platelets supplied to the healthcare ScopeThe report provides an overview of the global blood platelet market and analyzes market trends. It includes global revenue ($ million) for base year 2024, estimates for 2025 and a forecast period through 2030. The market is segmented based on platelet type, application, end user and region. The regions covered in this study include North America, Europe, Asia-Pacific, South America, and the Middle East and Africa, focusing on major countries in these report examines the significant trends and challenges that affect the market and blood donation landscape. It analyzes environmental, social and corporate governance (ESG) developments and discusses patents and emerging technologies related to the report provides an in-depth analysis of the global blood platelets market, with a comprehensive evaluation of the value chain from blood platelets collection to end-use applications. The scope encompasses the activities of blood collection organizations, which are responsible for the voluntary collection of blood donations in each country. These organizations play a critical role in separating, processing and storing platelets from donated blood and ensuring their timely and safe distribution to various healthcare market analysis covers the distribution of collected blood platelets to various end users, including hospitals, clinics, ambulatory surgical centers, cancer treatment centers, blood banks and transfusion centers. These facilities use blood platelets for multiple clinical and therapeutic report also examines the operational models of independent and government-funded organizations while also analyzing regulatory frameworks related to platelet donation, safety protocols and distribution standards across the report concludes with an analysis of the competitive landscape, providing a list of key organizations in the global blood platelet market. It also includes a dedicated section of company profiles that outlines details about leading market report includes: 45 data tables and 53 additional tables Overview and analysis of the global market for blood platelets, also known as thrombocytes Analyses of global market trends, with revenue data for 2022-2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global blood platelet market, along with a market share analysis by platelet type, application, end-user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, government policies and regulations and the impacts of macroeconomic variables Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses An assessment of the current market environment, innovation and prospects, emerging technologies, new developments, and products in the pipeline Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of the leading companies, including American National Red Cross, Vitalant, Canadian Blood Services, NHS Blood and Transplant, and Red Cross Society of China Key Attributes: Report Attribute Details No. of Pages 136 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $3.2 Billion Forecasted Market Value (USD) by 2030 $4 Billion Compound Annual Growth Rate 4.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of the Report Market Summary Market Dynamics and Growth Factors Emerging Technologies Segmental Analysis Regional Analysis Chapter 2 Market Overview Key Statistics About Blood Donations Blood Types Suitable for Platelet Donations Platelet Donation Process Porter's Five Forces Analysis Macroeconomic Factor Analysis Economic Growth and Healthcare Spending An Aging Population Worldwide Government Regulations and Health Policies Global Disease Burden Rising Inflation and Cost of Blood Donation Services Impact of Ongoing Tariffs Imposed by the U.S. on the Blood Platelet Market Chapter 3 Market Dynamics Market Drivers Increased Number of Surgical Procedures Better Awareness of the Importance of Blood Donations Rising Government Initiatives Prevalence of Chronic Blood-Related Disorders Market Restraints Elevated Risk of Infection in Platelet Transfusion Procedures High Cost of Platelet Transfusions Challenges in Blood Platelet Supply Chain and Logistics Shortage of Blood Donors Market Opportunities Increased Use of Donated Blood Platelets in Regenerative Medicine and Biotechnology Demand from Emerging Markets and Expanding Healthcare Infrastructure Chapter 4 Regulatory Landscape Regulatory Insights into the Blood Platelet Market Chapter 5 Emerging Technologies Emerging Technologies Advances in Pathogen Reduction Techniques for Platelet Collection Developments in Platelet Storage Systems Integration of AI and Automation in Blood Collection and Processing Chapter 6 Market Segmentation Analysis Market Breakdown by Platelet Type Apheresis-Derived Platelets Whole Blood-Derived Platelets Market Breakdown by Application Cancer Treatment Surgical Procedures Chronic Disease Treatment Traumatic Injury Thrombocytopenia (Non-Cancer Related) Platelet Function Disorder Market Breakdown by End-user Hospitals and Clinics Ambulatory Surgical Centers Blood Banks and Transfusion Centers Research Laboratories Cancer Treatment Centers Others Market Breakdown by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Key Takeaways Competitive Landscape List of Leading Organizations Across the Globe Key Developments and Strategies Partnerships and Collaborations Business and Service Expansions Technological Developments Regulatory and Legal Developments Chapter 8 Environmental, Social and Governance (ESG) Perspective Introduction to ESG Sustainability in the Blood Platelet Market Concluding Remarks Company Profiles AABB - Association for the Advancement of Blood & Biotherapies America's Blood Centers Australian Red Cross Lifeblood Belgian Red Cross-Flanders Blood Bank of Alaska Blood Centers of America Canadian Blood Services European Blood Alliance Finnish Red Cross Blood Service Indian Red Cross Society Japanese Red Cross Society Oneblood Sanbs The American National Red Cross Vitalant For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Blood Platelet Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900